JCA: joint clinical assessment
A joint clinical assessment (JCA) is the EU-level review of a new medicine's relative effectiveness under the HTA Regulation, shared by all Member States.
Joint clinical assessments are established by Regulation (EU) 2021/2282 and detailed in Implementing Regulation (EU) 2024/1381. A JCA compares the medicine with the comparators that Member States identify, across the populations and outcomes they care about, and produces a report on the available clinical evidence. It is a factual, scientific review: it describes the relative effectiveness and safety and the uncertainty in the data, but it does not conclude on added therapeutic value, does not set a price and does not decide reimbursement. Those remain national decisions that must give due consideration to the report.
The procedure starts when a product in scope is submitted to EMA. The Coordination Group's JCA subgroup collects the PICO questions from Member States and consolidates them into an assessment scope. The developer submits a dossier against that scope, including all clinical studies and analyses, and may not withhold data that national bodies would otherwise request. An assessor and co-assessor from two Member States draft the report, the developer may comment on factual errors, and the Coordination Group endorses the final version, which the Commission publishes with commercially confidential information redacted.
Since the first JCAs in 2025 the practical issues have become clear. Consolidated scopes can run to many PICOs, each needing its own analysis, including indirect comparisons where head-to-head data are missing. The dossier is prepared in parallel with the response to EMA's day 120 list of questions, which stretches regulatory and biostatistics resources. Developers also have to align three texts: the proposed indication in the SmPC, the population in the JCA scope and the label they expect to negotiate nationally.
What goes wrong: discovering a mandatory comparator too late to generate even an indirect comparison, submitting a dossier that answers the developer's own question rather than the PICOs, and missing the dossier deadline because the EMA timetable moved. Regulatory teams can help by sharing the expected CHMP opinion date early and flagging any indication wording changes agreed during the procedure. Companies that ran a joint scientific consultation before the pivotal trial tend to have fewer gaps in the PICO coverage, which is the strongest argument for engaging with the HTA process early.
Timing
The JCA dossier is due no later than 45 days before the envisaged CHMP opinion date, after the developer has received the assessment scope. The draft report is prepared during the remainder of the centralised procedure, with a short window for the developer to comment on factual accuracy. The Coordination Group endorses the report and it is published within 30 days of the Commission decision granting the marketing authorisation. Updates can be requested if the evidence changes materially, for example after a new indication.
Used in
Before preparing a submission, check the JCA scope and dossier requirements against the implementing rules in Workbench, which answers with cited sources.
Related terms
- HTA Regulation: Regulation (EU) 2021/2282 on health technology assessmentThe HTA Regulation, Regulation (EU) 2021/2282, sets up EU joint clinical assessments and joint scientific consultations for medicines from 2025.
- Pricing and reimbursement: national decisions on price and public fundingPricing and reimbursement are the national decisions, taken after authorisation, that set a medicine's price and whether a health system pays for it.
- Centralised procedure: single EU marketing authorisation via EMAThe centralised procedure grants one marketing authorisation valid across the EU and EEA after a single EMA assessment and a Commission decision.
- CHMP: Committee for Medicinal Products for Human UseThe CHMP is the EMA committee that assesses centralised applications and referrals for human medicines and adopts the opinions behind Commission decisions.
- Clock-stop: pause in the procedure timetableA clock-stop is a pause in a regulatory procedure's timetable while the applicant prepares responses to questions from the assessing authority.
Last updated